Virtual multi-institutional tumor board: a strategy for personalized diagnoses and management of rare CNS tumors - Takeaways - MDSpire

Virtual multi-institutional tumor board: a strategy for personalized diagnoses and management of rare CNS tumors

  • By

  • James L. Rogers

  • Thomas Wall

  • Alvina A. Acquaye-Mallory

  • Lisa Boris

  • Yeonju Kim

  • Kenneth Aldape

  • Martha M. Quezado

  • John A. Butman

  • James G. Smirniotopoulos

  • Huma Chaudhry

  • Christina I. Tsien

  • Prashant Chittiboina

  • Kareem Zaghloul

  • Orwa Aboud

  • Nicholas G. Avgeropoulos

  • Eric C. Burton

  • David M. Cachia

  • Karan S. Dixit

  • Jan Drappatz

  • Erin M. Dunbar

  • Peter Forsyth

  • Edina Komlodi-Pasztor

  • Jacob Mandel

  • Byram H. Ozer

  • Eudocia Q. Lee

  • Surabhi Ranjan

  • Rimas V. Lukas

  • Margarita Raygada

  • Michael E. Salacz

  • Matthew A. Smith-Cohn

  • James Snyder

  • Ariane Soldatos

  • Brett J. Theeler

  • Brigitte C. Widemann

  • Kevin A. Camphausen

  • John D. Heiss

  • Terri S. Armstrong

  • Mark R. Gilbert

  • Marta Penas-Prado

  • March 1, 2024

  • 0 min

Share

  • 1

    Multidisciplinary tumor boards (MTBs) enhance care coordination for patients with central nervous system (CNS) tumors through collaboration across various specialties.

  • 2

    Virtual MTBs allow participation from multiple institutions, facilitating expert guidance for rare CNS tumors and improving access to specialized care.

  • 3

    The NCI-CONNECT program focuses on advancing understanding and management of rare CNS tumors, reducing misdiagnosis and treatment complications.

  • 4

    Virtual neuro-oncology MTBs have been shown to be feasible and beneficial, enabling remote case reviews and referrals to specialized centers.

  • 5

    The transition to virtual MTBs during the COVID-19 pandemic has expanded participation and continues to optimize clinical practice for rare CNS tumors.

Original Source(s)

Virtual multi-institutional tumor board: a strategy for personalized diagnoses and management of rare CNS tumors

  • by James L. Rogers, Thomas Wall, Alvina A. Acquaye-Mallory, Lisa Boris, Yeonju Kim, Kenneth Aldape, Martha M. Quezado, John A. Butman, James G. Smirniotopoulos, Huma Chaudhry, Christina I. Tsien, Prashant Chittiboina, Kareem Zaghloul, Orwa Aboud, Nicholas G. Avgeropoulos, Eric C. Burton, David M. Cachia, Karan S. Dixit, Jan Drappatz, Erin M. Dunbar, Peter Forsyth, Edina Komlodi-Pasztor, Jacob Mandel, Byram H. Ozer, Eudocia Q. Lee, Surabhi Ranjan, Rimas V. Lukas, Margarita Raygada, Michael E. Salacz, Matthew A. Smith-Cohn, James Snyder, Ariane Soldatos, Brett J. Theeler, Brigitte C. Widemann, Kevin A. Camphausen, John D. Heiss, Terri S. Armstrong, Mark R. Gilbert, Marta Penas-Prado

  • March 1, 2024

Related Content

Challenges and Utilization of Immune Checkpoint Inhibitors in the Treatment of Lung Cancer

Perioperative risk stratification after resection of brain metastases: internal development and validation of the dominant lesion surgery score in a 20-year single-center cohort

Attention-Enhanced U-Net (AEU-Net): A Framework Utilizing Attention Mechanisms for Accurate Brain Tumor Segmentation with Multimodal MRI